Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
RAS mutations are frequently found among acute myeloid leukemia patients (AML), generating a constitutively active signaling protein changing cellular proliferation, differentiation and apoptosis. We have previously shown that treatment of AML patients with high-dose cytarabine is preferentially ben...
Main Authors: | Cornelia Brendel, Sabine Teichler, Axel Millahn, Thorsten Stiewe, Michael Krause, Kathleen Stabla, Petra Ross, Minh Huynh, Thomas Illmer, Marco Mernberger, Christina Barckhausen, Andreas Neubauer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4406710?pdf=render |
Similar Items
-
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
by: Mona Meyer, et al.
Published: (2009-11-01) -
Structure and catalytic properties of NRas and its oncogenic mutants
Published: () -
Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia
by: 土居崎, 小夜子, et al.
Published: (2014) -
Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
by: Shujuan Wang, et al.
Published: (2020-07-01) -
Identification of molecular targets of oncogenic NRAs and BRAF involved in regulation of melanoma cell proliferation
by: Petti, Carlotta
Published: (2007)